Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRL-101 SAD in healthy participants
NCT05667779Phase 1Completed
- Sponsor
- QurAlis
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing QRL-101 with Placebo (2 arms). Primary endpoint: Number of participants with one or more treatment emergent adverse events and serious adverse events at Day 10. Started Dec 2022; status: completed.
02
Drugs
QRL-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05667779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667779.